title: A child with severe hearing loss associated with maternal cisplatin treatment during pregnancy.
abstract: BACKGROUND
  Cisplatin is considered safe to use during the second and third trimesters of pregnancy in patients with cancer.
  
  
  METHODS
  A 34-year-old pregnant woman was diagnosed with cervical cancer. She received five weekly dosages of cisplatin and paclitaxel, starting at 26 5/7 weeks of gestation. An elective cesarean delivery was performed at 34 4/7 weeks of gestation. After birth, the neonate was diagnosed with severe bilateral perceptive hearing loss.
  
  
  CONCLUSIONS
  Cisplatin during the second and third trimesters of pregnancy may lead to fetal ototoxicity.
authors.affiliation: Department of Medical Oncology, Erasmus MC Cancer Institute, and the Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the Netherlands.
authors.forename: Eric C T
authors.initials: ECT
authors.lastname: Geijteman
authors.forename: Celesta W M
authors.initials: CWM
authors.lastname: Wensveen
authors.forename: Johannes J
authors.initials: JJ
authors.lastname: Duvekot
authors.forename: Lia
authors.initials: L
authors.lastname: van Zuylen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006312:Hearing Loss, Bilateral / Q000139:chemically induced* / Q000151:congenital; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D012720:Severity of Illness Index; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin